Park David J, Stoehlmacher Jan, Lenz Heinz-Josef
University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Division of Medical Oncology, 1441 Eastlake Ave #3440, Los Angeles, California, USA.
Curr Opin Pharmacol. 2003 Aug;3(4):378-85. doi: 10.1016/s1471-4892(03)00082-1.
In this post-genomic era, the individualization of chemotherapy through the study of pharmacogenetics is becoming an ever attainable reality. Keys to individual variations in drug response and toxicity are being identified through the study of drug targets, metabolizing enzymes, efflux and DNA repair systems at the genomic, mRNA and protein levels. Several promising pharmacogenetic candidates with predictive and/or prognostic value have been identified. These candidates, along with others yet to be identified, could in the near future allow for the tailoring of therapy with an ever increasing chemotherapeutic armamentarium. Well-designed and large prospective analyses, which include relevant pharmacogenetic parameters, are needed to confirm the initial clinical associations reported thus far.
